title: 13-cis-retinoic acid in silicone-fluorosilicone copolymer oil in a rabbit model of proliferative vitreoretinopathy.
abstract: The purpose of this study was to evaluate the effect of 13-cis-Retinoic Acid (RA) in Silicone-Fluorosilicone Copolymer Oil (SiFO) in a rabbit model of proliferative vitreoretinopathy (PVR). Rabbits underwent gas-compression vitrectomy. During gas-SiFO exchange, group 1 was injected with 1 ml (10 microg ml-1) 13-cis-RA in SiFO, group 2 with 1.5 ml (9 microg 1.5 ml-1) all-trans-RA in SiFO, group 3 with 1 ml SiFO alone, and group 4 with balanced salt solution (BSS). Groups 1-4 were also injected with 0.1 ml suspension of fibroblasts (75,000 0.1 ml-1) and 0.05 ml platelet rich plasma (70,000 0.1 ml-1), and were observed for 4 weeks. Group 5 was injected with SiFO alone, group 6 with 1 ml (10 microg ml-1) 13-cis-RA in SiFO, group 7 with 1.5 ml (9 microg 1.5 ml-1) all-trans-RA in SiFO, and group 8 with BSS. After 4 weeks, groups 5-7 underwent SiFO-BSS exchange. ERG and histopathology were performed to test for retinal toxicity in groups 5-8. The incidence of traction retinal detachment at 4 weeks was: group 1, 42.9%; group 2, 36.4%; group 3, 87.5%; and group 4, 88.9%. A significant difference in the incidence of PVR was noted between treated eyes (groups 1 and 2) and control eyes (groups 3 and 4) at 2, 3, and 4 weeks (P<0.05). No significant difference in the incidence of PVR was found between groups 1 and 2 during the same observation periods. ERG and histopathological studies showed no differences between the treated and the control fellow eyes (group 5-7) after 4 weeks. 13-cis-RA in SiFO (10 microg ml-1) is as effective as all-trans-RA in SiFO (9 microg 1.5 ml-1) in controlling the incidence of PVR when used for short term retinal tamponade and does not appear to be associated with retinal toxicity.
authors.affiliation: Schepens Eye Research Institute, Harvard Medical School, Boston, Massachusetts 02114, USA.
authors.forename: A A
authors.initials: AA
authors.lastname: Veloso
authors.forename: E F
authors.initials: EF
authors.lastname: Kadrmas
authors.forename: J M
authors.initials: JM
authors.lastname: Larrosa
authors.forename: M A
authors.initials: MA
authors.lastname: Sandberg
authors.forename: F I
authors.initials: FI
authors.lastname: Tolentino
authors.forename: M F
authors.initials: MF
authors.lastname: Refojo
mesh_terms: D000818:Animals; D004596:Electroretinography; D007429:Intraocular Pressure; D015474:Isotretinoin / Q000627:therapeutic use*; D011108:Polymers / Q000627:therapeutic use*; D011817:Rabbits; D012160:Retina / Q000166:cytology; D012163:Retinal Detachment / Q000628:therapy; D012828:Silicones / Q000627:therapeutic use*; D014212:Tretinoin / Q000627:therapeutic use; D018630:Vitreoretinopathy, Proliferative / Q000628:therapy*
chemical_list: D011108:Polymers; D012828:Silicones; C097657:silicone-fluorosilicone copolymer oil; D014212:Tretinoin; D015474:Isotretinoin